1 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Stronger health systems. Greater health impact. Access.

Slides:



Advertisements
Similar presentations
Accra, Ghana October 19-23, Extending Health Insurance: How to Make It Work DESIGN ELEMENT 4: BENEFITS PACKAGES AND COST CONTAINMENT 2/9/2014October.
Advertisements

An Essential Component of Health Systems Strengthening Presented on: May 23, 2011 Akiko Maeda Health, Nutrition & Population Network The World Bank.
Health Systems and Actors Tom Merrick, World Bank.
2 nd Conference of the African Health Economics and Policy Association (AfHEA) Saly – Senegal, 15 th - 17 th March 2011 Di McIntyre Chair, AfHEA Scientific.
Shaping UHC Policy for Post 2015: Opportunities & Risks Jeanette Vega MD, DrPH Managing Director of Health NHIS 10 Anniversary Conference Accra, November.
November 26, Fall Forum Alberta’s Pharmaceutical Strategy and Programs Policy Recommendations.
CAMBODIAN COUNTRY PROJECT IMPLEMENTATION Towards consolidating the existing social health protection schemes in Cambodia: assessment of best practices.
Reducing impoverishment from health payments: impact of universal health care coverage in Thailand Phusit Prakongsai 1 Supon Limwattananon 1,2 Viroj Tangcharoensathien.
MEDICINES SELECTION & FORMULARY MANAGEMENT
Assessing the impact of a policy on universal coverage on financial risk protection, health care finance, and benefit incidence of the Thai health care.
The Health Care Industry Part 2 - Medical Insurance Karen F. Nichols, MSA School of Allied Health Professions University of Nebraska Medical Center.
MEDICARE: PAST, PRESENT AND FUTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.
Building the Foundations for Better Health Health Services Organization.
SOCIAL HEALTH INSURANCE ASSOC PROF PHUA KAI LIT, PhD FLMI School of Medicine and Health Sciences Monash University (Sunway Campus) & ASSOC PROF PHUA KAI.
Active Pharmaceutical Management Strategies of Health Insurance Systems to Improve Cost-Effective Use of Medicines in Low- and Middle-Income Countries:
Implementation challenges of health financing policy reforms: experiences from Sub-Saharan Africa Peter Kamuzora Institute of Development Studies University.
Medical Insurance in China How is it different from India? Medical Insurance in China Global Conference of Actuaries Mumbai, February 2010.
Abstract 213 ICIUM: Antalya, Turkey. November 14-18, 2011.
Consultative Meeting on Accelerating the Attainment of MDG 5 in Kenya – August 27-28, 2014 Investing in Primary Health Care for reducing maternal & child.
Generating evidence for change: Implementing the post-ICIUM research agenda Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care.
Georgian Health Care 2020 Washington DC, February 1-2, 2010
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Health care reform in the Netherlands – role of the employer
1 HEALTH FINANCING REFORM PROPOSALS AND DEBATES National civil society consultation August 2008.
Health care system In Thailand.
How to determine medicines benefits policy and program needs?
To Accompany “Economics: Private and Public Choice 10th ed.” James Gwartney, Richard Stroup, Russell Sobel, & David Macpherson Slides authored and animated.
The Czech Health System – its Presence and Future Pavel Hroboň L.Dittrich.
International Health Policy Program -Thailand The 3 rd Global Symposium on Health Systems Research Cape Town International Convention Center, Cape Town,
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Universal Health Coverage – Achieving Access and Responsible Use of Medicines 2015 AGM Of The Pharmaceutical Society of Ghana Thematic Speaker Emmanuel.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
Cambodia1. 2 Cambodia Assessment Ung Phirun Chroeng Sokhan.
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
Summary from the Economics Track With thanks to all track participants, presenters, rapporteurs, moderators and organizers.
Health Care Facts and Guiding Principles for Health Care Reform Public Employees Union, Local #1.
Key issues in health care financing Di McIntyre. Objectives Introduce some key concepts Introduce a useful analytic framework Illustrate the analytic.
3 August 2004 Public Health Practice III: FINANCING PUBLIC HEALTH REFORM Thomas E. Novotny MD MPH University of California San Francisco Institute for.
Agenda Social Protection Updates on HCFS RMG 1. 2 Health Financing Strategy Implementation Plan Updates Presented by WHO HF DP Meeting 03 November 2013.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Re-thinking a roadmap to pursue Universal Health Coverage in Palestine – a discourse Awad MATARIA, PhD Health Economist World Health Organization – Eastern-Mediterranean.
Health challenges in an enlarged Europe Report from Parallel Session A1 Dr. Natasha Azzopardi Muscat Ministry of Health - Malta.
The Thai Experience on Achieving Universal Healthcare Coverage Samrit Srithamrongsawat Health Insurance System Research Office CHF best practice workshop.
Consumer-Driven Health Plans: Early Cost & Use Evidence with a Focus on Pharmaceuticals Stephen T Parente Jon B Christianson Roger Feldman August, 2004.
Social Health Insurance Policy Development. Presentation Policy process to date Constitutional mandate Policy context WHO Ranking Key objectives Future.
International Health Policy Program -Thailand Financing for Universal Coverage Experiences from Thailand Phusit Prakongsai, M.D. Ph.D. Viroj Tangcharoensathien,
Designing and Managing Medicines Benefits – Goals, Policy Options, Ethical Considerations Anita Katharina Wagner Department of Population Medicine Harvard.
International Health Policy Program -Thailand NHA TEAM International Health Policy Program Draft report presentation for external peer review October 7,
Improving Total System Performance & Public-private Partnership Dr. FUNG Hong Hospital Authority May 2001.
SURVEY OF HEALTH FINANCING SYSTEMS FOR ACCESS TO MEDICINES BY THE POOR IN RURAL AND URBAN PHILIPPINES A Research Study Funded by MeTA Philippines May 2010.
High Level Policy Dialogue – Cambodia Towards a Strong and Sustainable Health Sector Development ( Health Strategic Plan) 24 June, 2015 Cambodia.
HEALTH FINANCING MOH - HPG JAHR UPDATE ON POLICIES Eleventh Party Congress -Increase state investment while simultaneously mobilizing social mobilization.
SOCIAL HEALTH INSURANCE POLICY Presentation to Health Portfolio Committee 7 June 2005.
Evaluating ten years of universal health coverage in Thailand Viroj Tangcharoensathien, MD. Ph.D. Phusit Prakongsai, MD. Ph.D. International Health Policy.
Farid Abolhassani Social Health Insurance 15. Learning Objectives After working through this chapter, you will be able to: Define the principles of social.
Private Health Insurance
Farid Abolhassani The Changing World of Health Care Finance 13.
Health Care Connected: Next Generation Pharmacy February 13, 2016.
Ministry’s Vision for Universal Health Coverage Dr San San Aye Director (Planning) Department of Health Planning Ministry of Health National Dialogue on.
Overview of China’s health care reform Wen Chen, Ph.D., Professor Fudan School of Public Health March 21, 2016.
2nd African Decent Work Symposium: Yaoundé, Cameroon, 6-8 October THE SOCIAL SECURITY EXTENSION CHALLENGE: INCOME SECURITY AND HEALTH BENEFITS. Dr.
Health System Financing 1 |1 | Designing Health Financing System to Achieve Universal Coverage Ke Xu Health Systems Financing World Health Organization.
Health Care Financing Health Economic Course Series
Advancing Partnerships for Universal Health Coverage HANSHEP Workshop Dr. Rehana Ahmed 9 July 2015 Nairobi 1.
Coordination of health care in the EU Jakub Wtorek European Commission Directorate General for Employment, Social Affairs and Inclusion Unit: Active Ageing,
Susan Sparkes Department of Health System Governance and Financing, WHO Financing for universal health coverage: What does this mean for ending the HIV.
Health Care Financing: User Fees
Health Technology Assessment for Universal Health Coverage
Access to Essential Medicines
Health Financing Reforms in Countries of EMR – What Lessons for Sudan
Presentation transcript:

1 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Stronger health systems. Greater health impact. Access to Medicines through Universal Health Coverage (UHC): Golden Ring or Trojan Horse? Jonathan D. Quick, MD, MPH 1, 2 Kwesi Eghan 1 Anita Wagner 2 1 Management Sciences for Health 2 Harvard Medical School WHO Collaborating Center in Pharmaceutical Policy

2 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Amina’s story – the year 2000

3 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Is access to medicines through UHC a “Golden Ring” that improves health outcomes and financing equity?

4 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Or is access to medicines through UHC a Trojan Horse that threatens program viability?

5 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Access to medicines through UHC: Golden Ring or Trojan Horse? 1.Impact of out-of-pocket health and medicines spending in low and middle income countries 2.The growing movement for universal health coverage through strong health systems 3.Providing access to medicines through universal health coverage programs

6 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Unfair health financing – high out-of-pocket spending where total health spending is lowest Total health spending per person (international $), Log Scale Out-of-pocket (OOP) share of total health spending (%) Total health spending per person (international $), Log Scale

7 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Healthcare impoverishment – 150 million suffer financial catastrophe, 100 million impoverished WHO, World Health Report, 2010

8 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Tanzania, 2002, WHO essential medicines project Healthcare gap - 1/3 of poor people with acute illness receive none of the prescribed medicines % respondents with recent acute illness receiving prescribed medicines, Tanzania, 2002 Low Income High Income

9 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Access to medicines through UHC: Golden Ring or Trojan Horse? 1.Impact of out-of-pocket health and medicines spending in low and middle income countries 2.The growing movement for universal health coverage through strong health systems 3.Providing access to medicines through universal health coverage programs

10 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact The UHC movement – Growing “buzz” around UHC at all levels – country, regional, and global Stated interest in achieving UHC Implementing UHC reforms

11 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact The UHC approach – common core principles, country-specific adaptations  Contributions – based on ability to pay  General taxes, payroll taxes, other sources  Pooling of risk across the population  Cross-subsidization: rich to poor, healthy to sick  Most services with minimal or no out-of-pocket charge at the point of service Common Core Principles Country Models Vary Widely  Contributions in form of general taxes  Primarily financed by payroll contributions  Mix of tax-based financing, payroll, other sources

12 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact The UHC vision – “Access for all to appropriate health services at an affordable cost” (WHO, 2005) Laudable but Unrealistic Feasible and Inevitable Policy influence  High–level advocacy  Analysis and evidence  Country networks/capacity World Coverage: 40% OOP Expenditure: 60% World Coverage: 80% OOP Expenditure: 30% *WHA Resolution Geneva: WHO;

13 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Access to medicines through UHC: Golden Ring or Trojan Horse? 1.Impact of out-of-pocket health and medicines spending in low and middle income countries 2.The growing movement for universal health coverage through strong health systems 3.Providing access to medicines through universal health coverage programs

14 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Access to medicines through universal health coverage: What’s at stake? The Golden Ring greater health impact reduced medical impoverishment increased UHC acceptance The Trojan Horse excess demand for high cost medicines adverse impacts of cost controls more fraud and abuse

15 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Thailand – evolving expansion of coverage over more than four decades Sources: and McKinsey Co Year, policy, population coverage as of 2007 (Bold = still operational) 1963 – Civil Servants Medical Benefits Scheme 8% 1975 – Free medical care for low income 1990 – Voluntary public health insurance 1992 – Compulsory Social Security Scheme 13% 1993 – Free care for children 1995 – Free care for the elderly 2001 – Universal Coverage Scheme (UCS/”30-Baht”)75% Private Health Insurance 2% Year Out-of-pocket spending as percent of total health expenditures 70% of population covered (1995) 96% of population covered (2003) UHS/30 Baht Scheme (2001)

16 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Medicine cost escalation & response – Thailand’s Civil Servant Medical Benefit Scheme 2009 Measures2010 Measures  Drug use audits, 14 hospitals  Generic substitution  Prescribing restrictions  Proposal for uniform pricing  Audits expanded to 34 hospitals  Stronger generic substitution  Prescribing further restricted  Prescribing guidelines strengthened  Approval by “medical audit” team Source: IMS Thailand, 2011

17 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact UHC in action – moving toward UHC in Ghana through health spending and reform McKinsey Co : cash-and-carry fees 1990s: health sector decentralized 2000: New Patriotic Party wins with promise to replace cash-and-carry 2004: National Health Insurance Scheme created (NHIS) created Financed from: (a) health insurance tax, (b) formal sector employees, (c) member premiums, (d) investment income Accredited service providers: clinics, hospital, pharmacies, licensed chemical sellers (LCS) Out of pocket spending as percent of total health expenditure Less than 1% of population covered (2000) 45-70% of population covered (2008) NHIS created (2004)

18 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Ghana – expanding coverage, rising total claims, substantially increasing drug costs Source: Roberts and Reich, 2011, data from Mensah and Acheampong 2009

19 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Pharmaceutical management strategies for value in UHC - access, appropriate use, affordability, quality Payment Mechanisms Patient focused: co-payments, tiered co-payments, deductibles, coverage limits Provider focused: fee-for-service, capitation, case-based (“DRG”), pay-for-performance (P4P) Performance Management Contracting, purchasing Supply chain management Preferred pharmacy networks Quality of products and services Fraud detection systems Financial management, audits Medicine Benefits and Use Essential medicines lists Tiered formularies Clinical guidelines Treatment algorithms Provider and patient education Utilization review and feedback Cost Control – Value for Money Reimbursement lists and policies Generic/therapeutic substitution Step therapy, prior authorization Maximum allowable cost Reference pricing, other price controls

20 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact 7 proposed best practices for maximum health impact and value 1.Stakeholder engagement and communication – the public, patients, providers, healthcare managers, policy-makers, politicians 2.“Smart” therapeutics – priority health problems, outpatient coverage, essential medicines, clinical guidelines, 3.Value-based policy design – incentivize most appropriate use 4.Increased efficiency – generic/therapeutic substitution, efficient procurement and distribution systems 5.Reliable partners – accredited health providers and dispensing outlets, competitive sourcing from quality assured suppliers 6.Performance management – robust management systems for inventory management, drug use review, fraud detection 7.Culture of adaption – learning from others, benchmarking, routine monitoring, evaluation, based on what’s working and what isn’t

21 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact 7 common threats to medicines benefits – adverse health impacts, rising costs, poor quality 1.Competing political and policy goals – coverage, affordability, quality, industry interests 2.Weak governance and accountability structure – oversight body/board, public reporting, independent audit 3.Insufficient responsiveness to stakeholders – patients, the public, providers, private sector, others 4.Incomplete program design – focusing on some elements (e.g.benefits, co-payments) but not others (e.g. supply chain management, quality) 5.Failure to fully utilize needed expertise – success requires input from pharmaceutical management, public health, insurance, other experts 6.Inadequate adaptation to local context – modeling other countries or implementing “expert advice” without building on local strengths 7.Failure to ‘keep up’ and manage growth – essential medicine list/formulary, disease categories, population and geographic coverage

22 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Expanding the 3 dimensions of medicines coverage: Who? What? How much? WHO, World Health Report, What are they covered for? 3. How much are they covered for? 1. Who is covered?

23 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Summary and conclusions 1.Medicines benefits in UHC programs: Are essential for both health and fair financing goals Arguably pose the largest financial risk to UHC programs 2.There are critical research priorities, including: What is the best design for medicines benefit packages? How do specific coverage policies impact access, affordability, quality use, health and economic outcomes, sustainability? How can UHC programs best cover innovative high-cost medicines that may provide substantial benefits? 3.Expertise from multiple disciplines is required: Medicine, pharmacy, pharmaceutical management Economics, financing, accounting Law, ethics, information technology

24 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Amina’s story – the year 2011 – a happy ending?

25 Management Sciences for Health: 40 Years of Strengthening Health Systems for Greater Health Impact Medicines and UHC: Share experiences, plan policy and research agenda, learn more Friday, 18 November 2011, 7:45am to 8:45am, Azurit Health Insurance Coverage of Medicines: Policy and Research Recommendations MDS-3: Managing Access to Medicines and Other Health Technologies, 2011 Med icines and Insurance Coverage Initiative Med icines and Insurance Coverage Initiative WHO Collaborating Center in Pharmaceutical Policy